In 1980, Ludwig and colleagues described the histologic features of a newly identified chronic liver condition referred to as nonalcoholic steatohepatitis (NASH) and noted that the majority of the ...

According to recent reports from the Korean government, the incidence of alcoholic liver disease—previously the leading indication for liver transplantation—has been decreasing. This trend initially ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) can cause more serious liver conditions, such as liver failure. A new study, led by Lund University in Sweden, presents new data that ...

Endoplasmic reticulum (ER) stress and the unfolded protein response are often implicated in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), from simple steatosis ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

With the rising epidemic of obesity, metabolic syndrome, and type 2 diabetes mellitus in China, metabolic dysfunction-associated non-alcoholic fatty liver disease has become the most prevalent chronic ...

The new diagnostic tool, called the Fibroblast Activation Protein (FAP)-Index, could significantly improve how doctors identify people at risk of serious liver damage caused by metabolic fatty liver ...

A new blood test can help the early identification of liver scarring in liver disease. Learn more about this study.

The FDA expanded the indication for semaglutide (Wegovy) to treating adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), the agency announced. The glucagon-like peptide-1 ...

What Is Metabolic Dysfunction-Associated Steatohepatitis? Metabolic dysfunction-associated steatohepatitis, or MASH, is a form of liver disease. MASH occurs when fat accumulates in liver cells. Plenty ...